In this recent webinar, experts John Neal, Katya Svoboda, and David Byram examine the major policy shifts transforming the U.S. drug pricing landscape—including the accelerating impact of MFN models, evolving MFPs, PBM transparency reforms, and the growth of direct-to-patient models.
The discussion highlights how these policies intersect, the risks and opportunities they create for manufacturers, and the strategic implications that market access teams should consider as they prepare for 2026 and beyond.
Have questions about how MFN, evolving MFPs, and PBM reforms could affect your brand?
Meet with EVERSANA for a 30‑minute discussion to assess implications and potential paths forward.
Complete the form to access the full recording and learn how policy stacking is reshaping pricing, access, and market dynamics.
Author Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…